Abrocitinib(Cibinqo)

Cibinqo was first developed by Pfizer and approved for market by the FDA on January 14, 2022. 

Cibinqo is used to treat refractory, moderate to severe atopic dermatitis in adult patients who have poor response to other systemic treatments (such as hormones or biologics) or are not suitable for the above treatments.

Lucius Related Certificates

Drug Testing Report

Drug Marketing Authorization Certificate

Target of Action

JAK1

Dosage and Administration

Route and frequency of administration for Abrocitinib tablets: Oral, once daily.

The dosage of Abrocitinib tablets should be adjusted according to the patient's actual condition. Please consult your doctor for specific instructions.

Recommended reading: Dosage and Administration of Abrocitinib Tablets

Side Effects

Common side effects: Common cold, nausea, headache, etc.

Serious side effects: Serious infections, cancer, and immune system problems, etc.

Reference article: Side Effects of Abrocitinib Tablets

Use in Special Populations

Pregnancy: It is not known whether Abrocitinib will harm your unborn baby.

Breastfeeding: It is not known whether Abrocitinib passes into your breast milk. You should not take Abrocitinib while breastfeeding.

Daily Precautions

1. Inform patients that infections may occur while taking Abrocitinib. Instruct patients to tell their doctor if they develop any signs or symptoms of an infection.

2. Inform patients that patients receiving Abrocitinib treatment have an increased risk of developing shingles (herpes zoster), and some cases may be serious.

3. Inform patients that Abrocitinib may increase their risk of developing certain cancers, including skin cancer. Advise patients to undergo regular skin checks while taking Abrocitinib. Also advise patients to limit sun and ultraviolet light exposure by wearing protective clothing and using a broad-spectrum sunscreen.

from FDA，2023.12